T
Thomas C. Abshire
Researcher at Medical College of Wisconsin
Publications - 147
Citations - 7945
Thomas C. Abshire is an academic researcher from Medical College of Wisconsin. The author has contributed to research in topics: Von Willebrand disease & Von Willebrand factor. The author has an hindex of 42, co-authored 143 publications receiving 7265 citations. Previous affiliations of Thomas C. Abshire include Gulf Coast Regional Blood Center & Anschutz Medical Campus.
Papers
More filters
Journal ArticleDOI
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
Marilyn J. Manco-Johnson,Marilyn J. Manco-Johnson,Thomas C. Abshire,Amy D. Shapiro,Brenda Riske,Michele R. Hacker,Ray F. Kilcoyne,J. David Ingram,M L Manco-Johnson,Sharon Funk,Linda J. Jacobson,Leonard A. Valentino,W. Keith Hoots,George R. Buchanan,Donna DiMichele,Michael Recht,Deborah L Brown,Cindy A. Leissinger,Shirley Bleak,Alan R. Cohen,Prasad Mathew,Alison Matsunaga,Desiree Medeiros,Diane J. Nugent,Gregory Thomas,Alexis A. Thompson,Kevin McRedmond,J. Michael Soucie,Harlan Austin,Bruce L. Evatt +29 more
TL;DR: Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A.
Journal ArticleDOI
ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders
F. Rodeghiero,Alberto Tosetto,Thomas C. Abshire,Donald M. Arnold,Barry S. Coller,Paula D. James,Cindy E. Neunert,David Lillicrap +7 more
Journal ArticleDOI
Prevalence of von Willebrand disease in children : a multiethnic study
Eric J. Werner,Emmett H. Broxson,Eathyl L. Tucker,Donna S. Giroux,Justine Shults,Thomas C. Abshire +5 more
TL;DR: Von Willebrand disease is the most common congenital hemostatic disorder; its high prevalence is not limited to one ethnic group.
Journal ArticleDOI
Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors
Thomas C. Abshire,G. Kenet +1 more
TL;DR: Recombinant factor (rF)VIIa has been available to clinicians since 1996 and has an excellent safety record after almost three‐quarters of a million doses have been administered and thrombotic events have not increased despite a growing experience with higher dosing.
Journal ArticleDOI
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors.
J. Michael Soucie,Christy Cianfrini,Robert L. Janco,Roshni Kulkarni,Julie Hambleton,Bruce L. Evatt,Angela Forsyth,Sue Geraghty,Keith Hoots,Thomas C. Abshire,Randall Curtis,Ann D. Forsberg,Heather Huszti,Margaret Wagner,Gilbert C. White +14 more
TL;DR: It is concluded that ROM limitations begin at an early age, especially for those with severe and moderate disease, and that BMI is an important, potentially modifiable risk factor.